


## INFORMATION DISCLOSURE STATEMENT



Applicant : Goddard, et al. (as amended)  
App. No : 10/063,554  
Filed : May 2, 2002  
For : AN ANTIBODY TO A POLYPEPTIDE  
ENCODED BY A NUCLEIC ACID  
OVER-EXPRESSED IN NORMAL  
STOMACH TISSUE AND RECTUM  
TUMOR (as amended)

Examiner : Daniel E. Kolker

Art Unit : 1646

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 25, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing forty-four (44) references to be considered by the Examiner. Also enclosed are twenty-four (24) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

By:

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550

05/31/2005 HTECKLU1 00000034 10063544

02 FC:1806

180.00 OP

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/063,554
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1646
	Examiner	Daniel E. Kolker
SHEET 1 OF 3	Attorney Docket No.	GNE.3230R1C37

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number <i>Number - Kind Code (if known)</i> Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,194,596	03-16-1993	Tischer, et al.	
	2	5,350,836	09-27-1994	Kopchick, et al.	
	3	5,536,637	07-16-1996	Jacobs, K.	
	4	5,407,799	04-18-1995	Studier, F. W.	
	5	5,530,101	06-25-1996	Queen, et al.	
	6	5,856,090	01-05-1999	Epstein, D. M.	
	7	6,025,156	02-15-2000	Gwynn, et al.	
	8	6,124,433	09-26-2000	Falb, et al.	
	9	6,156,500	12-05-2000	Falb, Dean	
	10	6,162,604	12-19-2000	Jacob, Chaim O.	
	11	6,228,582 B1	05-08-2001	Rodier, et al.	
	12	6,395,306 B1	05-28-2002	Cui, et al.	
	13	6,414,117 B1	07-02-2002	Levinson, D. A.	
	14	6,465,185 B1	10-15-2002	Goldfine, et al.	
	15	6,498,235 B2	12-24-2002	Sheppard, et al.	
	16	6,562,343 B1	05-13-2003	Levinson, D. A.	
	17	6,572,862 B1	06-03-2003	Estes, et al.	
	18	6,645,499 B1	11-11-2003	Lal, et al.	
	19	6,730,502 B2	05-04-2004	Van Hijum, et al.	
	20	6,737,522 B2	05-18-2004	Sundick, et al.	

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/063,554
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1646
	Examiner	Daniel E. Kolker
SHEET 2 OF 3	Attorney Docket No.	GNE.3230R1C37

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	21	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. G-12, 403-404, 453. New York: Garland Publishing.	
	22	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	23	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	24	The 1991 Boehringer Mannheim Biochemicals Catalog, page 557, 1991.	
	25	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular &amp; Cellular Proteomics</i> 1.4, pp. 304-313.	
	26	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	27	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	28	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	29	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	30	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	31	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	32	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	33	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	34	ØRNTTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	35	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

[illegible]

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

**T<sup>1</sup>** - Place a check mark in this area when an English language Translation is attached.